The Possible Influence of Different Follow-up Modalities on Overall Survival in Ovarian Cancer (ECOvar)
The Possible Influence of Different Follow-up Modalities on Overall Survival in Ovarian Cancer: A Multicenter Observational Cohort Study
Sponsor: Klinik Hirslanden, Zurich
Terminated
Accrual rate fell far below needed accrual rate.
Other Ovarian Neoplasms trials with similar outcome
A observational or N/A phase clinical study on Ovarian Neoplasms and Patient Reported Outcome Measures, this trial is terminated or withdrawn. The trial is conducted by Klinik Hirslanden, Zurich and has accumulated 6 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
May 2024 — Jul 2024 [monthly]
Terminated
Status: Recruiting → Terminated
-
Jun 2022 — May 2024 [monthly]
Recruiting
▶ Show 1 earlier version
-
May 2022 — Jun 2022 [monthly]
Recruiting
First recorded
Dec 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Klinik Hirslanden, Zurich
- Manja Gideon Foundation
- Stiftung Swiss Tumor Institute
For direct contact, visit the study record on ClinicalTrials.gov .